Comparative analysis of annexin-1 in neuroepithelial tumors shows altered expression with the grade of malignancy but is not associated with survival

Modern Pathology

Volumn 22, Issue 12, 2009, Pages 1600-1611

  Schittenhelm, Jens ^a   Trautmann, Katrin ^a   Tabatabai, Ghazaleh ^a   Hermann, Caroline ^a   Meyermann, Richard ^a   Beschorner, Rudi ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Annexin 1; Astrocytoma; Central nervous system; Ependymoma; Glioma; Oligodendroglioma

Indexed keywords

ANNEXIN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; ASTROCYTE; ASTROCYTOMA; CANCER GRADING; CANCER SURVIVAL; COMPARATIVE STUDY; EPENDYMA CELL; EPENDYMOMA; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEUROEPITHELIOMA; OLIGODENDROGLIOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECOND CANCER; SUBVENTRICULAR ZONE; TISSUE MICROARRAY; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANNEXIN A1; ASTROCYTOMA; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL NUCLEUS; CHILD; CHILD, PRESCHOOL; EPENDYMOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGODENDROGLIOMA; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; TIME FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 71149088947     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.132     Document Type: Article

References (40)

1. Lim LH, Pervaiz S. Annexin 1: the new face of an old molecule. FASEB J 2007;21:968-975.
2. Smith PD, Moss SE. Structural evolution of the annexin supergene family. Trends Genet 1994;10: 241-246.
3. Christmas P, Callaway J, Fallon J, et al. Selective secretion of annexin 1, a protein without a signal sequence, by the human prostate gland. J Biol Chem 1991;266:2499-2507.
4. Solito E, McArthur S, Christian H, et al. Annexin A1 in the brain-undiscovered roles? Trends Pharmacol Sci 2008;29:135-142.
5. Johnson MD, Gray ME, Pepinsky RB, et al. Lipocortin-1 immunoreactivity in the human pituitary gland. J Histochem Cytochem 1990;38:1841-1845.
6. Eberhard DA, Brown MD, VandenBerg SR. Alterations of annexin expression in pathological neuronal and glial reactions. Immunohistochemical localization of annexins II I (p36 and p11 subunits), IV, and VI in the human hippocampus. Am J Pathol 1994;145:640-649.
7. Dreier R, Schmid KW, Gerke V, et al. Differential expression of annexins I, II and IV in human tissues: an immunohistochemical study. Histochem Cell Biol 1998;110:137-148.
8. Probst-Cousin S, Kowolik D, Kuchelmeister K, et al. Expression of annexin-1 in multiple sclerosis plaques. Neuropathol Appl Neurobiol 2002;28:292-300.
9. Alldridge LC, Bryant CE. Annexin 1 regulates cell proliferation by disruption of cell morphology and inhibition of cyclin D1 expression through sustained activation of the ERK1/2 MAPK signal. Exp Cell Res 2003;290:93-107.
10. D''Acquisto F, Merghani A, Lecona E, et al. Annexin-1 modulates T-cell activation and differentiation. Blood 2007;109:1095-1102.
11. Solito E, de Coupade C, Canaider S, et al. Transfection of annexin 1 in monocytic cells produces a high degree of spontaneous and stimulated apoptosis associated with caspase-3 activation. Br J Pharmacol 2001;133:217-228.
12. Alldridge LC, Harris HJ, Plevin R, et al. The annexin protein lipocortin 1 regulates the MAPK/ERK pathway. J Biol Chem 1999;274:37620-37628.
13. De BK, Misono KS, Lukas TJ, et al. A calcium-dependent 35-kilodalton substrate for epidermal growth factor receptor/kinase isolated from normal tissue. J Biol Chem 1986;261:13784-13792.
14. White IJ, Bailey LM, Aghakhani MR, et al. EGF stimulates annexin 1-dependent inward vesiculation in a multivesicular endosome subpopulation. EMBO J 2006;25:1-12.
15. Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev 2002;82:331-371.
16. Louis DN, Ohgaki H, Wiestler OD, et al. (eds). Pathology & Genetics: WHO Classification of Tumours of the Central Nervous System. International Agency for Research on Cancer Press: Lyon, 2007.
17. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170:1445-1453.
18. Watanabe K, Tachibana O, Sata K, et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6:217-223.
19. Schittenhelm J, Beschorner R, Simon P, et al. Diagnostic value of WT1 in neuroepithelial tumours. Neuropathol Appl Neurobiol 2009;35:69-81.
20. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33: 159-174.
21. Mittelbronn M, Capper D, Bunz B, et al. De novo erythropoietin receptor (EPO-R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival. Neuropathol Appl Neurobiol 2007;33:299-307.
22. Roseman BJ, Bollen A, Hsu J, et al. Annexin II marks astrocytic brain tumors of high histologic grade. Oncol Res 1994;6:561-567.
23. Tatenhorst L, Rescher U, Gerke V, et al. Knockdown of annexin 2 decreases migration of human glioma cells in vitro. Neuropathol Appl Neurobiol 2006;32:271-277.
24. Pepinsky RB. Phosphorylation of lipocortin-1 by the epidermal growth factor receptor. Methods Enzymol 1991;198:260-272.
25. Croxtall JD, Gilroy DW, Solito E, et al. Attenuation of glucocorticoid functions in an Anx-A1-/-cell line. Biochem J 2003;371:927-935.
26. Mulla A, Christian HC, Solito E, et al. Expression, subcellular localization and phosphorylation status of annexins 1 and 5 in human pituitary adenomas and a growth hormone-secreting carcinoma. Clin Endocrinol 2004;60:107-119.
27. Ruano Y, Mollejo M, Camacho FI, et al. Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multi-forme. Cancer 2008;112:1575-1584.
28. Herbert SP, Odell AF, Ponnambalam S, et al. The confluence-dependent interaction of cytosolic phos-pholipase A2-alpha with annexin A1 regulates en-dothelial cell prostaglandin E2 generation. J Biol Chem 2007;282:34468-34478.
29. Shen D, Nooraie F, Elshimali Y, et al. Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis. Human Pathol 2006;37: 1583-1591.
30. Petrella A, Festa M, Ercolino SF, et al. Annexin-1 downregulation in thyroid cancer correlates to the degree of tumor differentiation. Cancer Biol Ther 2006;5:643-647.
31. Paweletz CP, Ornstein DK, Roth MJ, et al. Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res 2000;60:6293-6297.
32. Mussunoor S, Murray GI. The role of annexins in tumour development and progression. J Pathol 2008;216:131-140.
33. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004;64:6892-6899.
34. Muracciole X, Romain S, Dufour H, et al. PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification. Int J Radiat Oncol Biol Phys 2002;52:592-598.
35. Huang H, Hara A, Homma T, et al. Altered expression of immune defense genes in pilocytic astrocytomas. J Neuropathol Exp Neurol 2005;64:891-901.
36. Liang Y, Bollen AW, Aldape KD, et al. Nuclear FABP7 immunoreactivity is preferentially expressed in infil-trative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma. BMC Cancer 2006;6:97.
37. Zheng PP, Pang JC, Hui AB, et al. Comparative genomic hybridization detects losses of chromosomes 22 and 16 as the most common recurrent genetic alterations in primary ependymomas. Cancer Genet Cytogenet 2000;122:18-25.
38. Kitange G, Misra A, Law M, et al. Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. Genes Chromosomes Cancer 2005;42:68-77.
39. Kuhlmann T, Gutenberg A, Schulten HJ, et al. Nogo-a expression in glial CNS tumors: a tool to differentiate between oligodendrogliomas and other gliomas? Am J Surg Pathol 2008;32:1444-1453.
40. Rousseau A, Nutt CL, Betensky RA, et al. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. J Neuropathol Exp Neurol 2006;65:1149-1156.